CLINICAL AND LABORATORY PROFILE OF CHILDREN WITH MITOCHONDRIAL DISORDERS
Main Article Content
Keywords
Mitochondrial diseases; genetic mutations; neuroregression; spectrometry
Abstract
Introduction: Mitochondrial disorders are a diverse group of inborn errors of metabolism caused by dysfunction of mitochondrial oxidative phosphorylation. They commonly present in children with non-specific neurological and systemic features, making early diagnosis challenging. This study aimed to characterize the clinical, biochemical, radiological, histopathological, and molecular profiles of pediatric mitochondrial disorders to improve early recognition and management.
Materials and Methods: A prospective observational study was conducted over one year at Indira Gandhi Institute of Child Health, Bengaluru, enrolling 67 children aged 1 month to 18 years with probable or definite mitochondrial disorders. Diagnosis was based on a composite scoring system integrating clinical, biochemical, radiological, and histopathological parameters. Investigations included blood tests, CSF analysis, tandem mass spectrometry, neuroimaging, muscle biopsy, and next-generation genetic sequencing where feasible.
Results: Leigh syndrome was the predominant phenotype (n=58). Neurological features such as seizures (78.2%), hypotonia (85.5%), dystonia (72.7%), and neuroregression (81.8%) were significantly more common in Leigh syndrome compared to other mitochondrial disorders. Elevated serum lactate was observed in 94.5% of Leigh syndrome cases. MRI revealed classic Leigh pattern lesions in 80% of affected patients. Genetic mutations were identified in all 17 cases where sequencing was performed, with a predominance of nuclear gene mutations. A high consanguinity rate (55.2%) was noted, correlating with the autosomal recessive inheritance pattern.
Conclusion: Pediatric mitochondrial disorders exhibit broad clinical heterogeneity, with Leigh syndrome being the most frequent presentation. A multimodal diagnostic approach combining clinical evaluation, biochemical testing, imaging, histopathology, and genetic analysis enhances diagnostic yield. Early suspicion, particularly in consanguineous populations, coupled with comprehensive evaluation, is crucial for timely intervention and genetic counseling.
References
2. Sharma N, Pasala MS, Prakash A: Mitochondrial DNA: Epigenetics and Environment. Environ Mol Mutagen. 2019, 60:668–82. 10.1002/em.22319
3. Ebihara T, Nagatomo T, Sugiyama Y, et al.: Neonatal-onset mitochondrial disease: clinical features, molecular diagnosis and prognosis. Arch Dis Child Fetal Neonatal Ed. 2022, 107:329–34. 10.1136/archdischild-2021-321633
4. Li X, Jiang O, Chen M, Wang S: Mitochondrial homeostasis: shaping health and disease. Curr Med. 2024, 3:5. 10.1007/s44194-024-00032-x
5. Suomalainen A: Mitochondrial roles in disease: a box full of surprises. EMBO Mol Med. 2015, 7:1245–7. 10.15252/emmm.201505350
6. Tripathi K, Ben-Shachar D: Mitochondria in the Central Nervous System in Health and Disease: The Puzzle of the Therapeutic Potential of Mitochondrial Transplantation. Cells. 2024, 13:410. 10.3390/cells13050410
7. Ardissone A, Ferrera G, Lamperti C, Tiranti V, Ghezzi D, Moroni I, Lamantea E: Phenotyping mitochondrial DNA-related diseases in childhood: A cohort study of 150 patients. Eur J Neurol. 2023, 30:2079–91. 10.1111/ene.15814
8. Hu C, Li X, Zhao L, Shi Y, Zhou S, Wang Y: Clinical Profile and Outcome of Pediatric Mitochondrial Myopathy in China. Front Neurol. 2020, 11:1000. 10.3389/fneur.2020.01000
9. Sofou K, De Coo IFM, Isohanni P, et al.: A multicenter study on Leigh syndrome: disease course and predictors of survival. Orphanet J Rare Dis. 2014, 9:52. 10.1186/1750-1172-9-52
10. Clemente-Suárez VJ, Redondo-Flórez L, Beltrán-Velasco AI, et al.: Mitochondria and Brain Disease: A Comprehensive Review of Pathological Mechanisms and Therapeutic Opportunities. Biomedicines. 2023, 11:2488. 10.3390/biomedicines11092488
11. Magro G, Laterza V, Tosto F: Leigh Syndrome: A Comprehensive Review of the Disease and Present and Future Treatments. Biomedicines. 2025, 13:733. 10.3390/biomedicines13030733
12. Sue CM, Hirano M, DiMauro S, De Vivo DC: Neonatal presentations of mitochondrial metabolic disorders. Semin Perinatol. 1999, 23:113–24. 10.1016/s0146-0005(99)80045-7
13. Popoiu T-A, Dudek J, Maack C, Bertero E: Cardiac Involvement in Mitochondrial Disorders. Curr Heart Fail Rep. 2023, 20:76–87. 10.1007/s11897-023-00592-3
14. Chinnery PF: Primary Mitochondrial Disorders Overview. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews®. University of Washington, Seattle: Seattle (WA); 1993.
15. Danhelovska T, Kolarova H, Zeman J, et al.: Multisystem mitochondrial diseases due to mutations in mtDNA-encoded subunits of complex I. BMC Pediatr. 2020, 20:41. 10.1186/s12887-020-1912-x
16. Theunissen TEJ, Nguyen M, Kamps R, et al.: Whole Exome Sequencing Is the Preferred Strategy to Identify the Genetic Defect in Patients With a Probable or Possible Mitochondrial Cause. Front Genet. 2018, 9:400. 10.3389/fgene.2018.00400